Soluble CD40L Levels Are Regulated by the −3459 A>G Polymorphism and Predict Myocardial Infarction and the Efficacy of Antithrombotic Treatment in Non-ST Elevation Acute Coronary Syndrome
- 1 July 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 26 (7), 1667-1673
- https://doi.org/10.1161/01.atv.0000222908.78873.36
Abstract
Objectives— Current evidence suggests the CD40–CD40L pathway as a key process in the development, progression, and outcome of acute coronary syndrome (ACS). The aim was to investigate the prognostic importance of soluble (s) CD40L levels, single nucleotide polymorphisms (SNP) in the CD40LG gene, and the relation between sCD40L and SNPs in patients with acute coronary syndromes (ACS). Methods and Results— Samples were obtained on admission from 2359 patients with non-ST elevation ACS randomized to an early invasive versus a conservative and to placebo controlled long-term dalteparin treatment in the FRISC-II study. The −3459 A>G SNP was identified as a novel regulator of sCD40L levels ( P =0.001). In the placebo-treated group, sCD40L levels above median were associated with a 2.5-fold increased risk of myocardial infarction (MI) ( P ≤0.001) but not with raised mortality. In the dalteparin treated group, sCD40L showed no association with MI ( P =0.75). Consequently, dalteparin treatment was effective in reducing the risk of MI only in patients with sCD40L levels above median. A combined assessment of troponin-T and sCD40L complemented the prognostic information on risk of MI. Conclusions— We identified a SNP in the CD40LG gene as a novel regulator of sCD40L plasma concentrations. Soluble CD40L levels above median reflect a prothrombotic state, which can be managed with the use of intense anti-thrombotic treatments.Keywords
This publication has 28 references indexed in Scilit:
- Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery diseaseJournal of Internal Medicine, 2005
- Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Short-Term Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic PatientsCirculation, 2005
- Soluble CD40L in peripheral artery diseaseThrombosis and Haemostasis, 2005
- Increased CD40 ligand and platelet–monocyte aggregates in patients with type 1 diabetes mellitusAtherosclerosis, 2004
- Soluble CD40LCirculation, 2003
- CD40 ligand is selectively expressed on CD4+ T cells and platelets: implications for CD40–CD40L signalling in atherosclerosisThe Journal of Pathology, 2003
- CD40 Ligation Induces Tissue Factor Expression in Human Vascular Smooth Muscle CellsThe American Journal of Pathology, 2000
- Reduction of atherosclerosis in mice by inhibition of CD40 signallingNature, 1998
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976